No title
Pancreatic cancer (PC) is a severe disease where only 8% of the patients survive longer than five years. Chemotherapy is the standard treatment option for patients with PC, either in adjuvant or palliative setting, however only 15% of the tumors are resectable. The poor prognosis highlights the need to identify new prognostic biomarkers and novel treatment options to improve patient outcome. This
